New cancer therapies: how workforce capacity impacts treatment implementation

New cancer therapies: how workforce capacity impacts treatment implementation

For his guest blog, Dr Martin Rolles explores how lack of workforce planning and specialist training can be a barrier to implementing new cancer therapies.
Read More
Leading experts join HPP and Avalere to examine readiness for radioligand therapy in the US

Leading experts join HPP and Avalere to examine readiness for radioligand therapy in the US

The Health Policy Partnership (HPP) and Avalere Health recently held a webinar on the use of radioligand therapy and readiness for its future integration in the US.
Read More
Neuroendocrine cancer and radioligand therapy: how patient involvement can shape the regulatory process

Neuroendocrine cancer and radioligand therapy: how patient involvement can shape the regulatory process

Nikie Jervis explores the history of regulatory approval for radioligand therapy in the UK, and the importance of patient involvement, in her guest blog.
Read More
Register for the virtual event: ‘Achieving readiness for radioligand therapy in the US’

Register for the virtual event: ‘Achieving readiness for radioligand therapy in the US’

On 3 November, The Health Policy Partnership and Avalere Health are holding an online event to examine the use of radioligand therapy in the US.
Read More
HPP to hold session on radioligand therapy at EMUC21

HPP to hold session on radioligand therapy at EMUC21

The Health Policy Partnership is hosting the session ‘Radioligand therapy: multidisciplinary collaboration for health system readiness’ at EMUC21 on 25 November.
Read More
Breaking down the inequalities that limit access to radioligand therapy

Breaking down the inequalities that limit access to radioligand therapy

In this guest blog, Dr John Buscombe discusses the difficulties that people with cancer have accessing radioligand therapy in the UK.
Read More
HPP launches policy brief at an event coinciding with ESMO 2021

HPP launches policy brief at an event coinciding with ESMO 2021

HPP was thrilled to launch its new policy brief 'Fostering system readiness in cancer care' on 21 September 2021, at an event coinciding with ESMO 2021.
Read More
Achieving system readiness for radioligand therapy in the UK: the event as it happened

Achieving system readiness for radioligand therapy in the UK: the event as it happened

On 9 September, The Health Policy Partnership (HPP) was pleased to host a webinar to launch the UK situation analysis report and policy action blueprint.
Read More
Join HPP webinar on system readiness in cancer care

Join HPP webinar on system readiness in cancer care

To coincide with ESMO 2021, The Health Policy Partnership is holding a webinar to launch the policy brief 'Fostering system readiness in cancer care'.
Read More
Register for launch of the radioligand therapy readiness assessment for the UK

Register for launch of the radioligand therapy readiness assessment for the UK

Join the The Health Policy Partnership on 9 Sept for an online event to launch the UK application of the Radioligand Therapy Readiness Assessment Framework.
Read More
Lessons learned as a radioligand therapy patient

Lessons learned as a radioligand therapy patient

In this guest blog, Josh Mailman recalls his experience of receiving radioligand therapy and the barriers to widespread access for patients.
Read More
Why a framework? The importance of a systems approach for radioligand therapy

Why a framework? The importance of a systems approach for radioligand therapy

The Radioligand Therapy Readiness Assessment Framework is a robust tool which can be used to generate information about integration of radioligand therapy into the health system.
Read More